ASCO: Sunitinib Improves PFS in Small-Cell Lung Cancer

A randomized, phase II trial showed improved progression-free survival in small-cell lung cancer with maintenance sunitinib vs placebo following standard chemotherapy, according to results presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

First Prospective Trial Shows Molecular Profiling Timely for Tailoring Therapy

A clinical trial has shown that patients and their physicians are eager to jump into the next generation of cancer care: analysis of an individual’s tumor to find and target genetic mutations that drive the cancer. Results of the study, CUSTOM, were presented at the 2013 ASCO Annual Meeting (Abstract 7513).

New Chaperone-Targeting Ganetespib Prolongs Survival in Advanced Lung Cancer

Adding the novel heat shock protein (HSP)-90 inhibitor ganetespib to docetaxel in salvage therapy is associated with prolonged overall survival (OS) compared to docetaxel alone among patients diagnosed with advanced adenocarcinoma lung cancer, report authors of the large randomized, first-in-class phase 2 GALAXY-1 clinical trial, presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.”